A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
← catalyst calendarNCT06208306 · readout in 103 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
700estimated
Sites
223
Countries
Argentina, Brazil, Bulgaria +29
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-11 | actual | When the study began enrolling |
| Primary completion | 2026-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease
Interventions
- Drug: Itepekimab (SAR440340) — also filed as REGN3500
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFIncidence of treatment-emergent AEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuation
measured Baseline up to Week 72
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed